1Pino CJ, Lou L, Smith PL, et al. A selectivc cyto pheretic inhibitory device for use during cardiopulrno nary bypass surgery[J]. Perfusion, 2012,27 ( 4 ) : 311- 319. 被引量：1
2Wang J, Ma HP,Zheng H. Blood loss after cardiopul monary bypass, standard vs titrated protamine : a me ta-analysis[J]. Neth J Med,2013,71(3) : 123-127. 被引量：1
3Noui N, Zogheib E, Walczak K, et al. Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device[J]. Perfusion, 2012,27 ( 3 ) : 214 -220. 被引量：1
4Menkis AH, Martin J, Cheng DC, et al. Drug, de- vices, technologies, and techniques for blood manage- ment in minimally invasive and conventional cardio- thoracic surgery:a consensus statement from the In- ternational Society for Minimally Invasive Cardiotho- racic Surgery (ISMICS) 2011[J]. Innovations (Phi- la), 2012,7 ( 4), 229-241. 被引量：1
5Shi D, Sun LL, Mi GJ, et al. Controlling ferrofluid permeability across the blood-brain barrier model [J]. Nanotechnology, 2014,25(7) :075101. 被引量：1
6Morisaki A, Nakahira A, Sasaki Y, et al. Is elimina- tion of cardiotomy suction preferable in aortic valve replacement? Assessment of perioperative coagula- tion, fibrinolysis and inflammation[J]. Interact Card- iovasc Thorac Surg,2013,17(3) : 507-514. 被引量：1
